4.4 Article

Bariatric surgery: an IDF statement for obese Type 2 diabetes

期刊

SURGERY FOR OBESITY AND RELATED DISEASES
卷 7, 期 4, 页码 433-447

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.soard.2011.05.013

关键词

-

类别

资金

  1. Allergan Inc, Irvine, CA, USA
  2. Ethicon, Ethicon Endo-Surgery Inc., Cincinnati, OH, USA
  3. MetaCure Inc., Mount Laurel, NJ, USA

向作者/读者索取更多资源

The International Diabetes Federation Taskforce on Epidemiology and Prevention of Diabetes convened a consensus working group of diabetologists, endocrinologists, surgeons and public health experts to review the appropriate role of surgery and other gastrointestinal interventions in the treatment and prevention of Type 2 diabetes. The specific goals were: to develop practical recommendations for clinicians on patient selection; to identify barriers to surgical access and suggest interventions for health policy changes that ensure equitable access to surgery when indicated; and to identify priorities for research. Bariatric surgery can significantly improve glycaemic control in severely obese patients with Type 2 diabetes. It is an effective, safe and cost-effective therapy for obese Type 2 diabetes. Surgery can be considered an appropriate treatment for people with Type 2 diabetes and obesity not achieving recommended treatment targets with medical therapies, especially in the presence of other major co-morbidities. The procedures must be performed within accepted guidelines and require appropriate multidisciplinary assessment for the procedure, comprehensive patient education and ongoing care, as well as safe and standardized surgical procedures. National guidelines for bariatric surgery need to be developed for people with Type 2 diabetes and a BMI of 35 kg/m(2) or more. (Surg Obes Relat Dis 2011;7:433-447.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据